首页> 外国专利> METHODS FOR REDUCING LIVER FIBROSIS AND TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS BASED ON ISHAK FIBROSIS STAGE

METHODS FOR REDUCING LIVER FIBROSIS AND TREATING LYSOSOMAL ACID LIPASE DEFICIENCY IN PATIENTS BASED ON ISHAK FIBROSIS STAGE

机译:基于ishak纤维化阶段的降低患者肝纤维化和溶酶体脂酶缺乏症的方法

摘要

The present invention provides methods of reducing liver fibrosis in a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ≥1 point reduction or a ≥2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration. Also provided are methods of treating a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ≥1 point reduction or a ≥2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration.
机译:本发明提供了减少具有溶酶体酸性脂肪酶(LAL)缺乏症的人类患者的肝纤维化的方法,其包括向该患者施用sebelipase alfa,其中已经确定该患者具有至少一个点的降低(例如,&#与给药前从患者体内获得的基线Ishak纤维化阶段相比,给药后的Ishak纤维化阶段减少了x2265; 1分或减少了#2265点(2分)。还提供了治疗具有溶酶体酸性脂肪酶(LAL)缺乏症的人类患者的方法,其包括向患者施用sebelipase alfa,其中已经确定该患者具有至少一个点降低(例如,≥ 1点)。与给药前从患者身上获得的基线Ishak纤维化阶段相比,给药后Ishak纤维化阶段的血氧饱和度降低(或降低2点)。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号